Q2 2020 Salarius Pharmaceuticals Inc Earnings Call
Bye and welcome to be Soliris pharmaceutical earnings webcast and conference call. At this time, all participants line or any listen only mode. After the speakers presentation. There will be a question and answer session to ask a question. During todays session you would need to press star one on your telephone keypad.
If you required for other assistance Please press star zero.
I would now like to handle the conference over to your host for today.
Greg bearing Tiberend strategic advisory. Thank you. Please go ahead.
Thank you Kelsey good afternoon, everyone and thanks for joining todays 2022nd quarter financial and corporate results call.
Earlier this afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months ended June Thirtyth 2020, which we encourage listeners to read the press release can be found them do section of celebrities pharma dot com their website.
It's also Chillers also filed the 10-Q this afternoon, which is available also on their website and it S. DC dot Gov.
Today, we'll be making certain forward looking statements about future expectations plans events and circumstances, including statements about our strategy future operations at the development of our lead investigational drug secular done stat, and our expectations regarding our capital allocation and cash resources.
These statements are based on our current expectations and you should not place undue reliance on these statements.
Actual results may differ materially due to risks and uncertainties, including those detailed in the risk factor section of Slurries Pharmaceuticals, 10-Q filed with the FCC and other filings, we make with the FCC from time to time.
So there is pharmaceuticals, just disclaims any obligation to update information contained in these forward looking statements.
I wouldn't read the result of new information future events or otherwise.
On today's call is David Arthur Director, and Chief Executive of serious Pharmaceuticals, who will provide update on Solaris is corporate and clinical achievements during the second quarter and its vision for the future. We also have Mark Rosenblum, Chief Financial Officer, who will review Slurries for second quarter 2020 financial.
Results with that I'll turn the call back to you David.
Thank you Greg Thank you to everyone for joining our conference call today.
This is an important time for Solaris Pharmaceuticals, we completed a transformative 2019 highlighted by our debut as a publicly traded company with our stock listed on the NASDAQ capital market.
We entered 2020, well position to achieve important corporate milestones and advanced clinical programs for several of them staff.
Our lead investigational drug candidate for Ewing's sarcoma and advanced solid tumors.
The second quarter 2020 in recent weeks have proven to be a timing substantial progress first of all areas.
Driven by several events that we believe validate our growth strategy and demonstrates the value of stuck with them stat.
In June Soliris presented early cyclic I'm stuck research during a virtual meeting of the pediatric oncology subcommittee of the F.D. AIDS Oncologic drugs Advisory Committee also known as ODAC. We were one of only for drug makers to participate in the two day meeting.
In July we strengthen in intellectual property portfolio protecting SEC, let them status with a new patent issued by the European patent office in all Solaris holds a 24 issued patents in the U.S. and abroad, all of which are directed to separate them stat for structurally similar compounds.
And most recently.
Soliris announced plans to expand its ongoing ewing's sarcoma clinical trial to include patients with sarcoma was that share a similar biology to ewing's also known as humans related Sarcomas. This provides the opportunity to develop second attempt stuff or an even broader patient population.
I will discuss the expansion of the Ewing's sarcoma trial as well is the ongoing clinical trials.
In using an advanced solid tumors in more detail in a bit but right now I'd like to turn the call over to Mark for a brief review of Solaris is second quarter Financial report Mark go ahead.
Thank you David.
For the three month period ended June Thirtyth 2020, Solaris reported a net loss of 1.8 million worth 13 cents per basic and diluted share compared with that was $1.9 million were 30 cents per basic and diluted share for the same period in 2019.
The loss from operations before other income for the three months ended June Thirtyth 2020 increased by $1 million.
Parents to the loss from operations for the same period last year.
Which was primarily due to an increase of.
Slide $6 million in research.
Development expenses, resulting from increased clinical trial expenses and drug manufacturing costs.
So Larry is also reported a net increase of point $7 million in general and administrative costs, resulting from Solaris is pres transformation into a public company and increased personnel expenses during the current quarter somewhat offset by lower professional fees a legal costs.
Fair to the same period in 2019.
As of June Thirtyth, 2020, total cash and cash equivalence was $7.1 billion.
$7.2 million excuse me compared to the $3.7 million at year end 2019. This does not however, painted accurate picture of the financial resources available to our company.
Recently on August the third 2020.
So areas completed a $6.2 million on underwritten public offering of its common stock.
Solaris intends to use the proceeds from the offerings to find ongoing company operations.
And the expansion is expansion of the Ewing's sarcoma clinical trial to include other ewing's related sarcoma.
This latest funding is not Solaris is only source of capital.
Did the genuinely interesting aspects of this Larry's story. This is the amount of non dilutive capital we have at our disposal.
In 2016, Solaris received an $18.7 million grant.
From the cancer Prevention and research Institute of Texas also known as secret of which we still have up to $9.1 million available under the secret contract subject to certain subjects and meeting certain requirements were approvals.
In addition, non dilutive funding from the National Pediatric Cancer Foundation has helped to fund our Ewing's sarcoma studies.
With these various funding sources, we believe malaria since the financial resources to advance or Ewing's sarcoma and advanced solid tumor clinical programs into late 2021.
With that I'd like to return the got back to David. Thank you Mark now, let's talk a little bit about what's happening with Solaris and what we can look forward to over the next few years.
As we discussed our goal is to maximize the potential of SEC, let them stat bring home to patients around the world battling cancer is caused by Dysregulated gene expression and maximize investor return.
As we look out over the remainder of 2020 in 2021 M. beyond we expect to not only advance our current clinical programs for SEC, let them staff in Ewing's sarcoma.
Including new weeks related sarcoma, and advanced solid tumors, but also explore other market opportunities, where we believe the SEC what that that could have a significant impact with patients fighting rare pediatric and other cancers.
Both our ewing's sarcoma and advanced solid tumor clinical trials have continued enrollment during the cobot 19 outbreak with all non clinical trial sites actively recruiting patients. Both studies remain a high priority at these sites.
To review both trials are designed is open label dose finding studies with primary objectives to characterize the pharmacokinetics characterize the safety profile and establish the maximum tolerated dose of SEC with them stat.
Secondary objective is to assess preliminary anti tumor activity.
No.
Do you in sarcoma clinical trial in the advanced solid tumor trial are continuing dose escalation and thus far early data from both trials suggest the plasma drug levels or the concentration of SEC, let them stuck in a patients plasma continued to increase in a dose proportional manner with no evidence of ups.
Plateau and exposure levels. This is important news is Solaris is now seeing plasma drug levels in patients.
Therefore above the levels, where pharmacological activity was noted during preclinical studies.
Following completion of dose escalation and determination of the maximum tolerated dose, which we hope to complete later this year.
We plan to begin dose expansion in not only patients with ewing's sarcoma, but also in patients with ewing's related sarcoma.
On 20 on July 29, we announced that a refractories ewing's sarcoma patients who had failed previous standard of care therapy and was treated with single agent secular them step therapy for six months.
Demonstrated a reduction in prospectively defined target lesions.
Target lesions generally represent a patients largest measurable tumors.
However, and unfortunately at eight weeks an increase in non target lesions resulted in an overall patient classification of progressive disease as designed as defined by the response evaluation criteria in solid tumors or persist.
Now this is important.
We believe the clinical observations, including this prospectively defined and measured reduction in target lesions by single agent SEC, let them stat treatment demonstrates preliminary drug activity.
So Larry's also believes this demonstration of drug activity, coupled with preclinical data supports the clinical research of SEC whatever that is a potential treatment for ewing related sarcoma.
This is why this is why we made the decision to expand our current clinical program to include patients with Ewing related sarcoma.
We believe Ewing related sarcoma is represent an opportunity to increase the number of patients that can potentially be treated by SEC, let them stat and also benefit from secular them step therapy.
Once maximum tolerated dose is established the ewing's sarcoma trial will enter a dose expansion phase that will enroll up to 20 Ewing's sarcoma patients.
And under the planned amendment to the trial protocol Ace second cohort.
The expansion pay phase will enroll up to 30 additional patients with either mix OID LIFO sarcoma, desmoplastic small round sell tumors or other cancers that share the FTT family gene rearrangements, all of which are known as Ewing related sarcomas.
Expanding the ongoing doing trial from 20 patients to 50 patients in the expansion phase to include patients that viewings related Sarcomas offers the potential as I mentioned earlier to develop SEC, let them step for an even broader patient population.
We believe this trial expansion is good for patients and we also believe it's good for investors.
We expect to initiate the expansion of viewing sarcoma trial, including you unrelated sarcoma as in the first half of 2021 with early data disclosures for both core cohorts in the second half of 2021.
Now in addition to the ongoing clinical trial in advanced solid tumors provides an opportunity to explore the potential of SEC, let them staff in treating cancers with mutations.
In other epigenetic enzymes or mutations in epigenetic complexes that may happen increased sensitivity to LSD.
One treatment for anti proliferative and or Immunomodulatory effects.
These mutations in Methyltransferase or a CDEL transfer ace enzymes and mutations in the Sweet sniff complex.
Kurt roughly 20% of solid tumor patients.
By using commercially available genetic screens, we believe we can potentially identify.
Potentially enrich our advanced solid tumor expansion cohort with patients that harbor. These sensitizing mutations this type of mutational profiling is becoming more common and could represent a significant opportunity fiscal areas.
Further we are exploring the use of sechler, then stat in combination with checkpoint inhibitors.
Type of immunotherapy designed to unleash immune attack on cancer cells now while checkpoint inhibitors are remarkable in batsmen in the treatment of cancer. They do not work in all cancer patients. In addition, among patients who do not do show an initial response to checkpoint inhibitors some patients can become refractory.
To these checkpoint inhibitors and experienced a return of the disease.
Now.
In July of this year researchers at the translational Genomics Research Institute in Arizona published a paper in a peer reviewed scientific journal plus one.
This paper represented in vitro studies investigating the ability of SEC with Devon stat to promote anti tumor immunity and T effector cell infiltration into types of ovarian cancer that both carry a specific mutation.
These two types of cancers were small cell carcinoma of the ovary hypercalcemia tight and ovarian clear cell carcinoma.
In simple terms. These studies demonstrated the SEC, let them stat may turn cold tumors concealed from the patience immune system into hot tumors that the immune system is able to identify these tumors with Vic could then respond to checkpoint inhibitor treatment. We believe this is a significant.
Phil opportunity and we're considering clinical trials that combine secular that stat with a checkpoint inhibitor.
Another exciting area that we are exploring SEC, let them stats potential to treat hematological cancers. Other LSD one inhibitors have clinically validated hematologic goal for blood cancers as attractive indications for LSD one inhibition.
However, we believe the SEC, let them stats differentiation may allow for certain advantages when treating these types of diseases.
We are considering a clinical trial studying SEC, let them stat in Hematological malignancies.
There's a lot to be excited about sex with them staff and our development programs. In addition to the early clinical data we have already disclosed we anticipate a number of additional potential milestones throughout the remainder of this year and into 2021, including data from our Ewing's sarcoma ewing's related sarcoma.
Advanced solid tumor trials.
In all the progress we have made since the beginning of the year and certainly over the past three months a substantial.
These accomplishments haven't turned position so areas for growth on a number of fronts over the next several quarters.
Now joining market me to address questions as Dr. Demers Senior Vice President clinical development and Dr., Dan Ellis Santee, Esteban director of research and business development.
With that I will now open the call to your questions Kelcy would you like to take over.
My pleasure at this time in order to ask your question. Please press star followed by the number one on your telephone keypad.
Again that its star one.
Our telephone keypad to ask your question at this time well pause for just a moment the compiled acuity roster.
Okay.
Q.
Yes.
And your first question comes from the line.
I'd.
No.
The benchmark it.
Thanks, very much for taking my questions and.
Congratulations on the progress this quarter.
When we think about combination trials with.
Hi, Y'all.
What are the most interesting combinations for several of them Scott in your opinion and would expect the immune oncology companies to sponsor of these combination trials.
Daniela would you like to take that question.
Yes. Thank you for the question.
So why the research has shown so far is that LLC, one inhibition and stuck with that in particular, what combine well with PD one PDL one.
The only four checkpoint inhibitors.
And we do think that as we advance or preclinical program.
And generate even more data.
The larger pharmaceutical companies would be interested as you know that checkpoint inhibitor has worked well in a subset of patients, but a large portion of patients remain refractory or lose sensitization to the checkpoint inhibitors.
And so there's a wide.
And open market for drugs like stuck with that can help either sensitized to checkpoint inhibitors or re sensitize.
Thank you thank you and telecom.
For the sponsor.
So sorry, just want to yeah, do expect the immune oncology companies large and oncology companies to sponsor combination trials.
So this is David.
I think that's a that's certainly something that's hilarious will want to pursue.
And when we begin those discussions we would very much like to have.
Additional data the in vitro and Nvvault data available to put together the most compelling case possible. So we will certainly be looking to partner with leaders in the checkpoint inhibitor field.
Thank you appreciate that another question I got as.
But the one patient who responded to if 86% decrease and prospectively defined target lesions. So why do you think the mone targets lesions did not decrease even if a single them started the systemically Asian.
Yes.
So this is David.
Dr. Merson redeem we'd like to take that question. Yes. This isn't the de Maria Thank you for the question.
The patient all the target lesions actually we saw shrinkage in all the target lesion and the number that you're referring to is the sum total up all the targeted lesions. What I think we have described there was some non targeted lesions, which are non measurable.
Which David earlier alluded to and they progress and because of that overall it was considered progressive disease.
In the targeted lesions.
We saw clearly in activity of the drug or something and the response that you mentioned.
Hi, Thank you.
Last question for me.
Given the broad competition LSD won.
I think the most of that so let's see one inhibitors are.
Universal Lawson phase to be in mollify pauses and mile.
Do you think the largest opportunities for all six of them start in general are.
In hematologic malignancies as opposed to so too much.
So this this is David I'll I'll make a comment and then perhaps ask.
Dr. Sop, yes, the bomb to to make any follow promise.
I think that there are a number of significant opportunities available SEC what them staff as you know we have or as we've discussed publicly we have a two pronged development approach speed to market with Ewing's sarcoma, which is just a scenario huge unmet.
Medical need.
Followed concurrently.
With the development cyclic and stop in areas that will expand the patient population now to your question.
I think at this point in time, if we put the patient first and identify the areas of highest unmet medical need and explore those areas with its effect that comes back to understand how best we can treat those patients I think that will naturally take us in the direction of the biggest.
Most valuable opportunities for the drugs. So at this time, we're exploring a number of opportunities across.
Solid tumors in our advanced solid tumor trial, we are exploring potential for being able to identify patients with mutations.
Mutated tumors that may be more sensitive to LSD, one therapy, which would would put together we think it's a very strong not only clinical recruitment strategy potentially a commercial strategy and as we mentioned we're looking at Hematological.
Malignancies and cancers and also.
Combinations with checkpoint inhibitors, where we could potentially not only provide benefit was sick with them, but also allow patients who are not currently benefiting from checkpoint levers to into.
To begin benefiting so I think at this point, it's difficult to say, what the biggest opportunity might be but I think if we keep the patient front and center and pursue areas of greatest unmet need we'll we'll get to the right answer.
Daniela do you have anything you'd like to add.
Yes, I just like to add that eating your right. A lot of are a lot of other else you want inhibitors are pursuing scheme indications as well as small cell lung cancer and they're pursuing those because that's where their drug has shown activity.
Second chance that has a differentiated mechanism of action, where we've shown the ability to inhibit not only alexey one majdic activity, but also with scaffolding said and that opens up the door time, we've seen activity in a lot of cancer types, where other outlets you want inhibitors have not seen activity.
So in addition to David's answer I'd, just like that you need to also understand how your molecule is inhibiting aloxi, one and that can help guide what indications whether they became or other solid tumors that you may show potential end.
Got it. Thank you guys. Appreciate all the answers I'll hop back in queue. Thanks.
Thank you for the question thank for joining the call.
Thank you.
Question comes from the line.
Ooh maybe lending.
Hi, Thanks for taking my questions in the one did you from Ladenburg.
Just a question I've discussed, but I'm question about.
The expansion, though the trial in do you gain related to coma.
Plan to the right now just wondering more color too.
Provide about the preliminary data that.
Value.
Well the expansion supported expansion also going forward, if you added hubertus the depletion.
The phase one and then for the first two I still going to separate two key words, such as a combined to one trial for regulatory approval.
The activity in both the utilizing and the you ladies cycle.
Thanks for the questions a doctor merger would you like to yes. So if I understand you have to question one related to that it'd be left two cohorts or one that I can one was what prompted us to go into the Ewing related sarcoma.
We havent ongoing.
Other tumor trials that also and dollar.
Some cycle of my patients that actually gave us some clinical.
Evidence and so that was one part of it in addition to.
Preclinical data supporting so that's that was the rationale to add using related sarcoma Gore.
Second question relating to weather really combined them a separate so the in the expansion phase as David mentioned earlier, there will be 20, Ewing's sarcoma patients and then there would be Turkey during a religious sarcoma patients.
And this this will allow us to further define safety tolerability, but more importantly to see any early.
Activity and then we will based on what we refer you observe we may.
And have some conversation a discussion that the health authorities to two to discuss what would be the next step but.
The short answer is that the Ewing expansion.
Expansion trials will have two different cohorts.
Got it is helpful. Maybe last question is any color on for that did not report.
On the Discos Gleason, you're going to stop at at the highest those are good.
Okay.
And the TV.
Yes, so I can take that this isn't that the we are currently at the.
Those levels six our cohort six out of seven.
We expect to get to our maximum tolerated dose and recommended phase $2 by and the end of this year of Q4.
Upon which we will initiate our expansion cohort and.
First half off next year.
Got it thanks for taking my questions.
Thank you for the question.
Thank you and your next question comes from the line of Hunter Diamond Wyman equity research.
Hi, everyone. Congrats on the recent quarter and also the financing.
So my questions were answered, but I'll have one or two more.
So I just wanted to get an update for the investors we talk to you on the humidity logic trial.
The second half sort of what you're anticipating happening is it just can be preclinical and I know maybe it's early days for that and then sort of the data that format is a strategy or an indication what's backing that.
Hunter. This is David let me, let me provide a little color to your question then I'll ask Daniela to step in and fill in.
Information around the preclinical.
Information that's available so what we have disclosed is that we're currently in the preclinical setting.
And I'll, let Daniela talked about that in a moment or ask her to talk about that in a moment and.
We also know that are we feel.
That this this approach to Hematological cancers has been validated by one of the other LSD one inhibitors and we further believe that several of them stats differentiation as a reversible inhibitor.
May allow us oh the ability to.
Provide even greater benefit in most patients.
So we hope to translate that.
Knowledge preclinical data and the opportunity to pursue hematological cancers in the clinic, we hope to train translate that.
Into a clinical trial sometime later this year, but we're not yet prepared to make that announcement.
Then yellow would you like to fill in some information on the preclinical data.
Yes.
As the we have.
The good data within several different teams cell line.
As David said on this space as well validated by other LSC one inhibitor.
Well Weve publisher collaborators have published with her first generation compound SP 25 to nine and that it has anti proliferative effect across and also while we also had some internal data showing activity with our lead compound SP 25, 77 or cycled on that.
That it has anti proliferative effects across several different keen cell lines as well as the ability to induce differentiation and seen increasing markers like see the 80 said.
So we do have a nice data package, there and that's why as David said, we're excited to make an announcement later this year in that space.
Great no perfect that was very useful.
My next question is just around the IP portfolio. So how many patents as the and I know there was an announcement, our PR and I think the European.
So how many patents the company have methods of user composition.
And then you know do they do you feel that you're going to be using some of these proceeds for more IP legal fees do you feel that or do you feel that the company sort of has secured secondly them that you know if its efficacious at this point.
And so hunter. We we currently have 24 patents issued that cover SEC around the world that covers cycle of them stock or structurally similar compounds. We have nine additional patents that are currently in the approval process in countries around the world.
And I can't remember exactly the list of countries.
But it's in the it's in the press release that went out recently and we can certainly get that for you.
Moving forward, we we aggressively maintain and defend our patent portfolio and are constantly looking to improve it.
Through additional patents that could represent method of use and and.
Other areas, where we can strengthen the portfolio so to answer your question.
Part of our ongoing operations is the maintenance and protection of these patents. So yes, our some of our ongoing funding and our future funding will certainly go towards protecting patent portfolio.
Perfect not makes a lot of sense and obviously in biotech the patents are much although expensive probably to procure they're much more useful then the software industry or something right, where everyone can knock off everyone. It's very hard to defend so biotech after that it's efficacious.
I mean, the patents will be critical right. So the big pharma doesn't just you know.
Enter the market. So okay. That's all I have in terms of questions on congrats again on the results in the financing.
Yes. Thank you for the question center, Thanks for participating.
Thank you.
Our next question comes from the line of Patrick Dolan with LP grows.
Mr Dueling favorite open.
David are you there it's Pat how are you, yes, Patrick how are you doing today. Good I just have a very quick question on all the clinical or preclinical work that's happening today.
Has it been as anticipated.
Better than anticipated or have there 'cause disappointments.
Well thanks for the question Patrick.
Yes.
By nature research is.
When you when we're in the business of research. We don't know the answer is that we're going to get and so we have.
We have experienced results that were very pleased with.
Point to the reason.
Our expansion of are.
Ewing study into use related trials thing a based on the fact that we have seen we feel we have seen demonstrated.
Drug activity in the clinic with.
The reduction of target lesions.
We have.
One of the study preclinical studies that we mentioned in the discussion today identified the ability into very you know.
Due to cancers.
With high unmet need the fact with mutations identifiable mutations.
Secondly, them step therapy can be can have a real benefit in patients suffering could potentially have a real benefit patients suffering from those those cancer. So again very positive news.
We have also found areas over the years.
Where the the activity of separate them stat.
Was not what we wanted to see and that's just is valuable to us as as the many many areas where we have seen.
Activity with SEC, what I'm stat, and we pursue those areas.
No. It allows us to to get focused and really pursue areas that we think are going to be the most benefit to patients and ultimately.
Drivers successes hilarious so to the short answer your question as we see at all and and we learn from every single one of the outcomes.
Okay, but my impressive as overall, you're saying.
Positives and you're actually expanded scope.
Is that correct.
Yes that is so so thank you for asking the follow up question. The answer is yes, we.
We.
So August patient.
We we looked at the data.
In the largest measurable to generally the largest measurable tuner tumors that.
That are identified prospectively by the physician we saw what we feel is demonstrated activity and that is that zero. We feel that is very positive information to see at this point in the clinical study and that coupled with preclinical information and the fact that we felt we had.
A positive interaction with the pediatric subcommittee of ODAC.
Let us to make the decision that that it was time to expand take advantage of all of this positive information and.
You know literally increase the number of patients that were going to be treating.
In in the Ewing's and Ewing's related sarcoma study by 150% we went from 20 to 53.
Patients and really opened up we think the door to looking at a much higher number of patient populations that may benefit from Sequans that so yes, sorry, I think it's fair to say that overall were very positive with.
We feel very positive with what we've seen recently.
Yeah, and that's how it came across to me I just I just wanted to tuck under Senate. So thank you very much.
My pleasure, thanks for calling in.
Thank you and your next question comes from the line.
HM.
Well being smart.
Thank you just got long I'll follow up question.
Regarding.
The comparison okay.
Sick of them start to others in the market so.
Is there any.
Similarities or differences, but we still feel celgenes reversible and elevate the one agent and do think they will be any read across from the Nivolumab plus ella's the agent studying lung cancer.
[noise] Daniela would you like to.
Provide some.
Some background on that question.
Sure.
Yes, so I am not to sell dinner BMS employees, but I can't speak too much about it I guess, what I've seen in the literature, but they do have the other reversible I will see one inhibitor. That's currently in clinic.
They have a different pharmacokinetic profile than we do that's a much longer half life.
The rationale behind why else do you want inhibition Navy.
Relating that tumor microenvironment may apply to their compound as well and I think that that's why they're pursuing.
This combination trial that you mentioned.
Mixed in.
Lung cancer patients I believe but you know if the company like Dms.
Formerly Celgenes molecule is now in clinic in this combination we view it as validation of where.
So Larry just thinking in advancing pick whatever that.
We do have different tox profile than Celgenes, where we don't see as much neutropenia and thrombocytopenia.
I think that now they're the same targets. So we do have.
Like I mentioned, not only differential activity, but different safety profile. So there are opportunities for us.
And like I said Celgene has no validated the combination for us on so we're excited for that.
Yes. Thank you.
Appreciate it.
You're welcome.
Thank you so much further question.
And there are no for the question. Thank you at this time.
Yes. So this is David I'll wrap up.
As we discussed today Solaris is all we believe Solaris is on strong footing operationally developmentally and financially.
And we're continuing to work hard to maintain our momentum and I believe we are.
I'd like to just take a moment to thank our employees for their dedication and loyalty, especially during this cobot 19 outbreak and to our stakeholders for their continued support as we work to bring hope to patients and their families battling ewing's sarcoma hearing related sarcoma as in other cancers caused by Dysregulated gene expression.
So I appreciate your time today your attention today and I'd like to extend my sincerest wishes of good health to all thank you for participating.
Thank you, ladies and gentlemen, John in todays conference call. You may now disconnect presenters. Please standby.